Compare ALM & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALM | ICUI |
|---|---|---|
| Founded | N/A | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Medical/Dental Instruments |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 4.6B |
| IPO Year | 2016 | 1995 |
| Metric | ALM | ICUI |
|---|---|---|
| Price | $18.04 | $175.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $22.33 | ★ $169.00 |
| AVG Volume (30 Days) | ★ 6.6M | 294.2K |
| Earning Date | 05-20-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 100.62 |
| EPS | N/A | ★ 1.96 |
| Revenue | N/A | ★ $2,231,262,000.00 |
| Revenue This Year | $817.94 | N/A |
| Revenue Next Year | $158.05 | $4.46 |
| P/E Ratio | ★ N/A | $89.34 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.98 | $112.50 |
| 52 Week High | $24.41 | $192.85 |
| Indicator | ALM | ICUI |
|---|---|---|
| Relative Strength Index (RSI) | 60.83 | 51.45 |
| Support Level | $12.47 | $138.91 |
| Resistance Level | $19.35 | $191.07 |
| Average True Range (ATR) | 1.09 | 3.81 |
| MACD | 0.43 | -1.80 |
| Stochastic Oscillator | 87.64 | 9.02 |
Almonty Industries Inc is engaged in the development of the Sangdong Mine in South Korea, and the Company is currently mining, processing, and shipping tungsten concentrate from the Panasqueira tin and tungsten mine in Covilha, Castelo Branco, Portugal (Panasqueira Mine). Additionally, the Company is evaluating its molybdenum project with inferred mineral resources on a separate property adjacent to the tungsten orebody at the Sangdong Mine, its Valtreixal tin and tungsten mine project located in Western Spain in the province of Zamora (Valtreixal Mine), and the newly-acquired Gentung Browns Lake tungsten project located in Montana, USA (Gentung-Browns Lake Project). The company has two geographical locations: the Iberian Peninsula (Spain and Portugal) and the Republic of Korea.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.